IGC Pharma Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
IGC Pharma Stock Forecast and Price Target
In recent months, notable analysts have provided yearlong price targets for IGC Pharma, with the average target coming in at $3.25. If it were to be achieved, this would result in a potential upside of approximately 606.52 percent from the most recent closing price in April, 2024. The high end is $3.25, and the low is $3.25. If you're interested in investing in this company, why not also look at its competitors to see how they are doing?
606.52% Upside
IGC Pharma Fair Value Forecast for 2023 - 2025 - 2030
In the last year, IGC Pharma's Price has grown by 100.00%, rising from $0.00 to $0.00. For next year, analysts predict Fair Value of $0.51, which would mean an increase of 100.00%. Over the next six years, experts predict that IGC Pharma's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$733.51 | Buy/Sell | $636.99 | 14.18% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$146.14 | Buy/Sell | $174.55 | 16.33% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$131.20 | Buy/Sell | $130.51 | 8.61% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$25.40 | Buy/Sell | $32.87 | 20.08% |
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
12
|
$397.48 | Buy/Sell | $457.59 | 13.21% |
IGC Pharma Revenue Forecast for 2023 - 2025 - 2030
In the last three years, IGC Pharma's Revenue has fallen from $4.07M to $910.00k – a 77.64% decrease. For next year, analysts predict Revenue of $2.19M, which would mean an increase of 140.39%. Over the next seven years, experts predict that IGC Pharma's Revenue will grow at a rate of 89.88%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$883.20 | Buy/Sell | $961.26 | 18.89% |
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$44.85 | Buy/Sell | $58.15 | 21.52% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$158.42 | Buy/Sell | $220.47 | 39.50% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$40.13 | Buy/Sell | $44.86 | 12.14% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$143.31 | Buy/Sell | $245.24 | 50.02% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.57 | Buy/Sell | $11.73 | 3.72% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$233.85 | Buy/Sell | $284.08 | 27.00% |
| CTLT Stock Forecast | Catalent | Hold |
15
|
$55.92 | Buy/Sell | $49.29 | 13.56% |
| CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$65.34 | Buy/Sell | $87.92 | 43.86% |
IGC Pharma EBITDA Forecast for 2023 - 2025 - 2030
IGC Pharma's EBITDA has seen impressive growth In the last three years, rising from $-6.72M to $-10.91M – a growth of 62.35%. In the next year, 0 analysts estimate that IGC Pharma's EBITDA will decrease by 14.87%, reaching $-9.29M. According to professional forecasts, in 2030, IGC Pharma's EBITDA will decrease by 15.05%, reaching $-9.27M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$41.59 | Buy/Sell | $55.60 | 44.75% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$193.33 | Buy/Sell | $315.92 | 101.73% |
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$139.26 | Buy/Sell | $145.00 | 14.53% |
IGC Pharma EBIT Forecast for 2023 - 2025 - 2030
In the last three years, IGC Pharma's EBIT has grown by 68.66%, rising from $-6.86M to $-11.57M. According to 1 analysts, IGC Pharma's EBIT will fall by 15.30% in the next year, reaching $-9.80M. Professionals believe that By 2030, IGC Pharma's EBIT will fall to $-9.88M – a 14.59% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PRGO Stock Forecast | Perrigo Co PLC | Outperform |
16
|
$31.94 | Buy/Sell | $44.75 | 23.98% |
| NEOG Stock Forecast | Neogen | Outperform |
16
|
$12.14 | Buy/Sell | $37.00 | 40.03% |
| CORT Stock Forecast | Corcept Therapeutics | Buy |
16
|
$22.80 | Buy/Sell | $35.67 | 66.67% |
IGC Pharma EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last year, IGC Pharma's EPS has grown by 100.00%, rising from $-0.16 to $0.00. For next year, analysts predict EPS of $-0.15, which would mean an increase of 100.00%. Over the next six years, experts predict that IGC Pharma's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£14.08 | Buy/Sell | £28.89 | 121.88% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Buy |
14
|
$7.82 | Buy/Sell | $17.83 | 117.39% |
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$13.47 | Buy/Sell | $29.44 | 152.41% |
.jpg)